Jefferies analyst Anthony Petrone reiterated a Buy rating on Haemonetics Corp (NYSE: HAE) yesterday and set a price target of $125. The company’s shares closed yesterday at $105.51, close to its 52-week high of $108.37.
According to TipRanks.com, Petrone is a 4-star analyst with an average return of 15.0% and a 55.8% success rate. Petrone covers the Healthcare sector, focusing on stocks such as Varex Imaging Corporation, Varian Medical Systems, and Mallinckrodt.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Haemonetics Corp with a $105 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $108.37 and a one-year low of $41.10. Currently, Haemonetics Corp has an average volume of 769K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Haemonetics Corp. is a healthcare company, which engages in the development and distribution of hematology products and solutions. It operates through the following geographical segments: Japan, EMEA (Europe, the Middle East, and Africa), North America Plasma, and All Other.
